CL2016003283A1 - Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a procedure for its preparation - Google Patents

Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a procedure for its preparation

Info

Publication number
CL2016003283A1
CL2016003283A1 CL2016003283A CL2016003283A CL2016003283A1 CL 2016003283 A1 CL2016003283 A1 CL 2016003283A1 CL 2016003283 A CL2016003283 A CL 2016003283A CL 2016003283 A CL2016003283 A CL 2016003283A CL 2016003283 A1 CL2016003283 A1 CL 2016003283A1
Authority
CL
Chile
Prior art keywords
ezetimibe
rosuvastatin
oral administration
procedure
preparation
Prior art date
Application number
CL2016003283A
Other languages
Spanish (es)
Inventor
Yong Ii Kim
Jae Hyun Park
Jong Soo Woo
Seung Jun Lee
Ha Young Jeong
Kyong Soo Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2016003283A1 publication Critical patent/CL2016003283A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>SE PROPORCIONA UNA FORMULACIÓN COMPUESTA SÓLIDA PARA LA ADMINISTRACIÓN ORAL QUE INCLUYE; UNA PORCIÓN CORRESPONDIENTE A GRÁNULOS HÚMEDOS DE EZETIMIBA QUE INCLUYE EZETIMIBA QUE SE GRANULA POR VÍA HÚMEDA UTILIZANDO UN GRANULADOR DE LECHO FLUIDO; Y UNA PORCIÓN CORRESPONDIENTE A UNA MEZCLA DE ROSUVASTATINA QUE INCLUYE ROSUVASTATINA O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES.</p><p> A SOLID COMPOSITE FORMULATION IS PROVIDED FOR THE ORAL ADMINISTRATION THAT INCLUDES; A PORTION CORRESPONDING TO EZETIMIBE WET GRANULES THAT INCLUDES EZETIMIBE THAT IS GRANULATED BY WET DAMAGE USING A FLUID MILK GRANULATOR; AND A PORTION CORRESPONDING TO A ROSUVASTATIN MIXTURE THAT INCLUDES ROSUVASTATIN OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS. </p>

CL2016003283A 2014-06-25 2016-12-21 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a procedure for its preparation CL2016003283A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (en) 2014-06-25 2014-06-25 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
CL2016003283A1 true CL2016003283A1 (en) 2017-07-28

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003283A CL2016003283A1 (en) 2014-06-25 2016-12-21 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a procedure for its preparation

Country Status (10)

Country Link
KR (1) KR101977785B1 (en)
AR (1) AR100977A1 (en)
BR (1) BR112016030111A2 (en)
CL (1) CL2016003283A1 (en)
EC (1) ECSP16096477A (en)
JO (1) JOP20150154B1 (en)
SG (2) SG10201811586YA (en)
TW (1) TWI700100B (en)
UY (1) UY36190A (en)
WO (1) WO2015199356A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016539A3 (en) * 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
KR102206535B1 (en) * 2016-11-29 2021-01-22 한미약품 주식회사 Oral composite tablet comprising ezetimibe and rosuvastatin
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR20200137243A (en) 2019-05-29 2020-12-09 콜마파마(주) Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
TW202224681A (en) * 2020-08-25 2022-07-01 南韓商大熊製藥股份有限公司 Single dosage form of a pharmaceutical composition for the treatment or prevention of hypertension and hypercholesterolemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (en) * 2007-09-05 2009-07-09 박재섭 The golf club using moving ball
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
US8927021B2 (en) * 2009-07-28 2015-01-06 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszventarsasag Granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
DK2844233T3 (en) * 2012-05-01 2020-07-13 Althera Life Sciences Llc ORAL TABLE CONSTRUCTION CONSISTING OF A PROVIDED COMBINATION OF ROSUVASTATIN AND EZETIMIB FOR THE TREATMENT OF HYPERLIPIDIA AND CARDIOVASCULAR DISEASES

Also Published As

Publication number Publication date
AR100977A1 (en) 2016-11-16
BR112016030111A2 (en) 2017-08-22
TW201625223A (en) 2016-07-16
WO2015199356A1 (en) 2015-12-30
KR20160000762A (en) 2016-01-05
SG10201811586YA (en) 2019-02-27
TWI700100B (en) 2020-08-01
JOP20150154B1 (en) 2021-08-17
ECSP16096477A (en) 2017-01-31
KR101977785B1 (en) 2019-05-14
UY36190A (en) 2015-10-30
SG11201610748RA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
CL2016003283A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a procedure for its preparation
CL2016002517A1 (en) Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
PH12019500176A1 (en) Heterocyclic compounds and ther uses
MX2021006035A (en) Stable cannabinoid formulations.
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
CR20160191A (en) COMPOUNDS DERIVED FROM BICYCLIC PIRIDYL FUSED TO RING AS FGFR4 INHIBITORS
DK3674298T3 (en) SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE AND THEIR USE FOR THE PREPARATION OF MEDICINAL PRODUCTS
CL2018001199A1 (en) Comprimido de tres capas que comprende un compuesto de formula i, tenofovir alafenamida y emtricitabina; su uso en el tratamiento de una infeccion por vih.
EP3256149A4 (en) Formulations for oral administration of active agents
CR20170077A (en) OPTIONALLY CONDENSED HEREROCICLYL PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES
EA201790892A1 (en) CRYSTAL FORMS OF 5-CHLOR-N4- [2- (DIMETHYLPHOSPHORIL) PHENYL] -N2- {2-METHOXY-4- [4- (4-METHILPIPERAZIN-1-IL) PIPERIDIN-1-IL]} PYRIMIDIN-1-IL -DIAMINE
CL2017000716A1 (en) Rorc2 pyrrolopyridine modulators substituted with methyl and trifluoromethyl and methods of use thereof
CL2014001828A1 (en) Dual-release oral dosage system comprising doxylamine and pyridoxine and / or its analogs, metabolites and salts thereof; oral dosage form dual release; pharmaceutical kit; use to relieve symptoms of nausea and vomiting, including those of pregnancy.
BR112017008993A2 (en) Methods and Compositions Specifically for the Treatment of Attention Deficit Disorder
EA201500821A1 (en) Derivatives of 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purines, their use as pharmaceuticals and pharmaceutical compounds
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
IL264880A (en) Formulations for oral administration of active agents
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
DK3307239T3 (en) Formulations for administration of RSV and norovirus antigens to the small intestine
DK3107568T3 (en) Formulations for administration to the small intestine
DOP2018000032A (en) HERBICIDE COMPOSITION AND PROCESS TO PREPARE IT
CL2017001466A1 (en) A process for the manufacture of idalopirdine
HUP1600415A2 (en) Pimavanserin salts for the manufacture of pharmaceutical formulations
FI20165034A (en) Granulation of materials comprising ash
MA41216A (en) TOTAL SYNTHESIS OF TRIOXACARCIN DC-45-A2 AND PREPARATION OF TRIOXACARCIN ANALOGUES